VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
TRDA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
TRDAEntrada Therapeutics, Inc.
$5.03$195M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksTRDAFinancials

Entrada Therapeutics, Inc. (TRDA) Income Statement

7Y historyFree accessUpdated daily

Revenue collapsed to $898.0K in 2026Q2 from $94.7M in 2024Q2 while R&D and SG&A of $45.9M produced a -50.1% operating margin, and gross margin swung violently from 100.0% to -22.8% across the period, indicating no stable cost-to-revenue foundation.

Income StatementBalance SheetCash FlowRatios

TRDA Income Statement

Annual statement

TRDA Income Statement

Entrada Therapeutics, Inc. (TRDA) annual income statement — 7-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Sales/Revenue3.98M25.42M210.78M129.01M0000
Revenue Growth %-93.54%-87.94%63.38%-----
Cost of Goods Sold1.69M4.1M0000326K104K
COGS % of Revenue-16.11%------
Gross Profit2.29M21.32M210.78M129.01M00-326K-104K
Gross Margin %57.48%83.89%100%100%----
Gross Profit Growth %--89.88%63.38%--100%-213.46%-
Operating Expenses173.45M177.32M163.77M132.18M97.25M51.13M26.34M11.82M
OpEx % of Revenue-697.55%77.7%102.45%----
Selling, General & Admin40.39M41.05M38.47M32.29M30.64M15.2M5.24M3.61M
SG&A % of Revenue-161.48%18.25%25.03%----
Research & Development134.75M142.27M125.31M99.88M66.61M35.93M21.1M8.22M
R&D % of Revenue-559.65%59.45%77.42%----
Other Operating Expenses-1.69M-6M000000
Operating Income-171.16M-156M47.01M-3.16M-97.25M-51.13M-26.67M-11.82M
Operating Margin %-4303.82%-613.66%22.3%-2.45%----
Operating Income Growth %--431.83%1586.75%96.75%-90.21%-91.72%-125.53%-
EBITDA-170.33M-151.9M50.78M-321K-95.35M-50.01M-26.34M-11.72M
EBITDA Margin %-4282.83%-597.55%24.09%-0.25%----
EBITDA Growth %-45.14%-399.11%15920.56%99.66%-90.67%-89.86%-124.75%-
D&A (Non-Cash Add-back)-1.14M4.1M3.77M2.84M1.9M1.12M326K104K
EBIT-161.19M-142.83M66.48M12.06M-91.98M-51.16M-26.52M-11.82M
Net Interest Income9.97M019.47M15.22M0000
Interest Income9.97M019.47M15.22M2.63M000
Interest Expense00002.63M000
Other Income/Expense9.97M13.17M19.47M15.22M2.63M-31K144K6.72M
Pretax Income-161.19M-142.83M66.48M12.06M-94.62M-51.16M-26.52M-5.1M
Pretax Margin %-4053.16%-561.84%31.54%9.34%----
Income Tax192K924K859K18.74M0000
Effective Tax Rate %-0.12%-0.65%1.29%155.45%0%0%0%0%
Net Income-161.39M-143.75M65.63M-6.68M-94.62M-51.16M-26.52M-4.65M
Net Margin %-4057.98%-565.48%31.13%-5.18%----
Net Income Growth %-56%-319.04%1081.69%92.93%-84.95%-92.88%-470.51%-
Net Income (Continuing)-161.39M-143.75M65.63M-6.68M-94.62M-51.16M-26.52M-5.1M
Discontinued Operations00000000
Minority Interest00000000
EPS (Diluted)-3.81-3.471.68-0.20-2.79-1.60-0.84-4.44
EPS Growth %-54.39%-306.55%940%92.83%-74.38%-90.48%81.08%-
EPS (Basic)--3.471.76-0.20-2.79-1.60-0.84-4.44
Diluted Shares Outstanding42.37M41.37M39M33.05M31.29M31.22M31.25M1.05M
Basic Shares Outstanding42.37M41.37M37.31M33.05M31.29M31.22M31.25M1.05M
Dividend Payout Ratio--------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Losses outpacing revenue recovery

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Top Line Collapsed to Immateriality

Entrada's quarterly revenue collapsed from $94.7M in 2024Q2 to $898.0K in 2026Q2, with the most recent quarter declining 53.9% year over year, according to reported income statements, suggesting whatever previously drove the top line has largely evaporated.

The sequence of growth rates (-10.6%, -55.3%, -65.2%, -97.9%, -91.8%, -96.5%, -95.7%, -53.9%) points to a one-time revenue source that exhausted itself during 2024 rather than a business scaling with adoption, since the deceleration was abrupt and has not meaningfully reversed. Importantly, the most recent 'improvement' to -53.9% growth comes off an already tiny base of $875K, so investors should treat it as a low-base artifact rather than evidence of a genuine recovery trajectory.

Gross Margin Lacks Stable Foundation

As reported in TRDA's financial statements, gross margin swung from 100.0% in 2025Q2 to -22.8% in 2025Q3 when $38.4M of COGS met $1.6M of revenue, then to 8.0% in 2026Q1, signaling no stable cost-to-revenue relationship.

The recurring 100.0% gross margin quarters reflect periods with zero recorded COGS, which suggests revenue is likely non-product in nature (for example, licensing or milestone recognition) rather than manufactured product sales. The $38.4M COGS charge in 2025Q3, roughly 24x that quarter's revenue, may indicate a write-off or cost absorption tied to a specific event; because it is not yet clear whether such charges recur, any normalized margin assumption warrants further investigation.

R&D Absorbs an Unsustainable Share

Based on Entrada's reported figures, R&D expense climbed from $28.6M in 2024Q1 to $35.4M in 2026Q2 while SG&A held near $10M, leaving the company absorbing roughly $46M of quarterly operating costs against sub-$1M revenue, a ratio that dominates the P&L.

SG&A discipline appears genuine, moving only from $9.4M to $10.5M across ten quarters, which implies management has kept overhead contained while directing spending toward pipeline work. R&D, however, grew about 24% even as revenue fell more than 98%, meaning the expense base appears deliberately decoupled from current commercial output — a posture that only makes sense if management believes pipeline value can eventually replace the lost revenue, though the income statement alone cannot confirm that.

Non-Operating Items Flatter Net Loss

Stock-based compensation reached $9.9M in 2026Q2 versus $3.7M in 2024Q1, while the $42.8M net loss trailed the $45.0M operating loss, suggesting non-operating items are cushioning reported earnings, based on Entrada's disclosed income statements, warranting closer inspection.

The consistent gap between operating and net results — for instance, 2025Q1's -$21.8M operating loss reported as -$17.3M net loss, and 2024Q2's $53.4M operating income reported as $55.0M net income — implies a recurring non-operating contribution, plausibly interest income, that is propping up the bottom line independent of operations. With SBC more than doubling to $9.9M in 2026Q2 and representing a substantial share of the $45.0M operating loss, dilution-adjusted economics look weaker than headline EPS of -$1.01 conveys.

Peak-Earnings Era May Be Behind

The strongest challenge to TRDA's narrative is that 2024's profitability — $55.0M net income on $94.7M revenue in 2024Q2 — appears episodic, since subsequent quarters show operating losses near $42M with revenue under $2M, based on reported figures.

A short-seller would likely emphasize that the operating loss has proven sticky at $42M–$47M per quarter across eight consecutive periods while revenue fell to negligible levels, so cost structure has not adjusted in proportion to the revenue loss and losses appear structurally entrenched rather than transitional. They would also note that gross margin of 100.0% in five of ten quarters, when revenue is this small, offers no evidence of pricing power or durable unit economics, and may indicate that peer comparisons on margin (peers such as ARWR and EDIT also post 100% gross margins) mask very different underlying revenue quality.

TRDA — Frequently Asked Questions

Quick answers to the most common questions about buying TRDA stock.

What was Entrada Therapeutics, Inc.'s (TRDA) revenue in 2025?

For fiscal year 2025, Entrada Therapeutics, Inc. (TRDA) reported total revenue of $25.4M.

Is Entrada Therapeutics, Inc. (TRDA) profitable?

Entrada Therapeutics, Inc. (TRDA) reported a net loss of $143.8M for the fiscal year ending 2025.

What is Entrada Therapeutics, Inc.'s operating profit margin?

Entrada Therapeutics, Inc. (TRDA) reported an operating income of $-156.0M, resulting in an operating profit margin of -613.7%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Entrada Therapeutics, Inc.'s gross profit and gross margin?

Entrada Therapeutics, Inc. (TRDA) generated $21.3M in gross profit for the year, representing a gross profit margin of 83.9%. This demonstrates the company's core pricing power and production efficiency.